Experience with fibrinolytic therapy of vascular occlusive disease.
1. There may well be a place for streptokinase therapy in selected patients with chronic arterial occlusion, but the emphasis should be on developing information on selection criteria. 2. Efficacy and safety have been established for the use of streptokinase in occluded AV cannulae, but this may be more of historical than contemporary importance. 3. Although more investigation is required to define the role of lytic therapy in retinal vascular occlusion and in the hemolytic uremic syndrome, the preliminary results are encouraging and merit further attention.
D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000601:surgery; D001166:Arteriovenous Shunt, Surgical; D002404:Catheterization; D002908:Chronic Disease; D004351:Drug Resistance; D005263:Femoral Artery / Q000601:surgery; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006435:Renal Dialysis; D012161:Retinal Artery; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use
D006493:Heparin; D013300:Streptokinase